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ABSTRACT
Iatrogenic antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is not exceptional. Many cases of small vessel vasculitis 
induced by anti-thyroid drugs (ATD), mainly propylthiouracil (PTU), have been reported. We present a case of AAV related to another ATD: 
benzylthiouracil (BTU) and review the literature. An 84-year-old man with a 4-year history of multinodular goitre with hyperthyroidism was 
treated with BTU. He presented an acute syndrome with weakness, fever, epigastric pain and abdominal distension. Lactate and lipase tests 
were normal. An abdominal scan showed a thrombosis of the splenic artery with splenic infarction. We excluded a hypothesis of associated 
embolic aetiology: atrial fibrillation, atrial myxoma, intraventricular thrombus or artery aneurysm. Exploration of a possible prothrombotic 
state (complete blood count, haemostasis tests, activated protein C resistance, factor V Leiden, protein C, S, antithrombin III) gave normal 
results. Tests for antinuclear antibodies (ANA) and antiphospholipid antibodies (APL) were negative. However, testing for p-ANCA, with 
antimyeloperoxidase (MPO) specificity, was positive: 120.6 CU (N<20.0). We did not find other systemic manifestations, except a non-specific 
kidney failure. BTU was discontinued without steroids or immune-modulating drugs. Subsequently, symptoms disappeared progressively 
and titres of ANCA fell until normalization, 4 months later. Many patients treated with BTU present a high prevalence of ANCA, mainly, but 
not exclusively, directed against MPO. Vasculitis, however, remains an uncommon complication. The mechanism of this anomaly remains 
to be elucidated. Some studies suggest the possibility of an autoimmune reaction initiated by drug bioactivation mediated by neutrophil-
derived MPO. The present observation is particular because the involved drug was BTU and clinical expression was unusual.
LEARNING POINTS
• ANCA-associated vasculitis related to anti-thyroid drugs is not exceptional, particularly in patients receiving long-term therapy with 
thioamides.
• Clinical manifestations are highly variable.
• Treatment consists firstly of stopping the anti-thyroid drug. Introduction of steroids and/or immunosuppressive therapy depends on the 
severity of organic impairments. Prognosis is less severe than primary ANCA vasculitis.
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INTRODUCTION
Antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) is a group of small vessel systemic vasculitides. ANCAs were 
first discovered in 1982 by Davies et al. in patients’ sera with pauci-immune segmental necrotizing glomerulonephritis[1]. ANCAs are 
autoantibodies targeted against antigens present in the cytoplasm of neutrophils and monocytes. The most common target antigens are 
proteinase 3 (PR3) and myeloperoxidase (MPO)[2]. Anti-thyroid drugs (ATD) are widely used in the treatment of thyroid disorders. Adverse 
effects related to the use of this medication include agranulocytosis, cutaneous rash, toxic hepatitis and induced lupus-like syndrome. AAV 
is not an exceptional complication. It has mainly been reported with propylthiouracil (PTU)[3]. We present here a case of ANCA-anti-MPO-
associated vasculitis related to another thioamide: benzylthiouracil (BTU).
CASE DESCRIPTION 
An 84-year-old male with a clinical history of multinodular goitre and hyperthyroidism presented an acute syndrome with fever and 
epigastric pain. Past history included hypertension, chronic obstructive airways disease and benign prostatic hyperplasia. Thyrotoxicosis 
was diagnosed 4 years previously. FT4 was 23.2 pmol/l (12–22 pmol/l), TSH was <0.005 mUI/l (0.27–4.2 mUI/l) and TSH receptor antibodies 
were negative. The patient had been treated and well controlled on BTU 100 mg/day. On admission, blood pressure was 160/82 and his pulse 
was regular (88/min). The patient was complaining of an epigastric pain with important abdominal distension and a rebound tenderness at 
the left upper quadrant. A small multinodular goitre was palpable. The obtained laboratory data are shown in Table 1. An abdominal scan 
showed a distal thrombosis of the splenic artery with splenic infarction. There was no artery aneurysm. An ECG showed a left bundle branch 
block with lateral repolarization abnormalities. There were no occasional cardiac arrhythmias or atrial fibrillation on Holter monitoring. 
Echocardiography did not find a thrombus in the left ventricular cavity, no arguments for an endocarditis, but did show an anteroseptal 
akinesis. The laboratory exploration of a possible prothrombotic state: complete blood account, haemostasis tests, activated protein C 
resistance, factor V Leiden, protein C, S, antithrombin III, showed normal results. A HIV serology test was negative. We detected a moderate 
hyperhomocysteinaemia of 21.8 (N:5–15 μmol/l). Testing for antinuclear antibodies (ANA), antiphospholipid antibodies (APL) and ANCA 
anti-PR3 was negative. However, testing for p-ANCA, with anti-MPO specificity, was clearly positive: 120.6 CU (N<20.0). We did not find 
other systemic manifestations, except a kidney failure stage 3A, without haematuria or proteinuria. BTU was discontinued without steroids 
or immune-modulating drugs. Subsequently, clinical symptoms progressively ceased. Two months later, thiamazole 10 mg was introduced 
because of a relapse of the thyroid disorder. 
Four months after the cessation of BTU, titres of ANCA-MPO fell until normalized. Serum concentrations of TSH and FT4 were appropriate, 
and creatinine was stabilized at 140 μmol/l.
Variable Reference range
1st hospital
 admission
8 weeks after 
cessation of BTU
4 months after 
cessation of BTU
Haemoglobin 13.5–17.5 g/dl 14.6
Introduction of 
thiamazole
13.1
WBC 4–10 G/l 7.3 5.7
Platelets 150–400 G/l 313 275
CRP  <5 mg/l 100 <5
Creatinine 59–104 μmol/l 113 140
Urea 2.5–7 mmol/l 6.2 12.2
Proteinuria <0.05 g/l <0.05 <0.05
TSH 0.27–4.2 mUI/l 0.32 1.36
FT4 12–22 pmol/l 14.6
NT-proBNP <300 ng/l 3,529 2,836
Lactate 0.5–2.2 mmol/l 1.05
Lipase 13–60 UI/l 25
ANCA anti-MPO N<20.0 CU 120 Negative
Table 1. Laboratory data obtained at initial assessment 
and at follow-up
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SUMMARY OF CASES
The first induced AAV case was reported in 1992 by Stankus and Johnson, and was related to PTU[4]. In 2002, Tieulie et al. described the first 
case caused by BTU[5]. Since then, 17 other observations of induced AAV related to BTU have been reported (see Table 2).
89% of cases were female,probably reflecting the female preponderance of thyrotoxicosis. The average age of affected patients was 38.8 
years (range 8 to 84 years). All of patients presented Graves’ disease,while the average duration of exposure to BTU was 32 months (range 
6 to 120 months).
Renal involvemeklet was the most common manifestation (83%), followed by general symptoms (fever, weight loss, anorexia, asthenia) in 
56% of patients, skin manifestations in 39%, joint pain in 33%, pulmonary vasculitis with alveolar haemorrhage in 22%, with neurological/
neuropsychiatric manifestations having been reported in two cases (11%). Renal biopsy showed necrotizing glomerulonephritis in 8 cases 
(44%) or crescentic glomerulonephritis in 6 (33%). In cases of skin involvement, biopsy revealed a non-specific leucocytoclastic cutaneous 
vasculitis. Immunofluorescence was always pauci-immune. 
A p-ANCA pattern was present in 78 %, whilec-ANCA was seen in only one case (#16). Undifferentiated positive ANCAs were reported in 3 
observations (17%). In 89%, ANCAs were directed against MPO. PR3-ANCAs were negative in all sera, when tests were performed.Therapy 
consisted ofstopping BTU. Additional treatment with steroids and/or cyclophosphamide was initiated in patients presenting severe organic 
impairment (89%). In 72%, therapy resulted in improvement. Concurrently,titresof ANCAs decreased or disappeared progressively but 
persisted in some cases (#4, #10, #13). In 11%, renal function declined (#2, #15). Death occurred in one case related to Klebsiella pneumoniae 
septicaemia (#16).
DISCUSSION
Our 84-year-old patient had been treated with BTU for 4 years. He did not present severe organic impairment but had sudden pain and 
fever, with detection of splenic artery thrombosis within a positive ANCA-MPO context. Exclusion of other aetiologies and resolution of 
symptoms after discontinuing BTU suggested a close relationship between the ATD and clinical manifestations. Exposure duration to BTU 
in our case was long. According to Gunton et al., there is a significant association between duration of therapy, mainly with PTU, and ANCA 
positivity (p<0.0001). Testing patients receiving long-term anti-thyroid medication seems to be interesting [16]. A p-ANCA pattern with anti-
MPO specificity seems to be the most common in BTU-induced AAV. To our knowledge, a single abdominal vascular involvement has never 
been observed previously. Manifestations of AAV related to ATD are variable; they may consist of non-specific constitutional symptoms[17] 
or may involve vessels in the skin, kidneys, respiratory tract or peripheral nerves[18]. The prevalence of ANCA in patients treated with 
ATD varies from 4 to 46% while the prevalence of AAV is lower: 0–1.4%. Slot et al. demonstrated that ANCA positivity was significantly 
related to the use of ATD[19]. The presence of ANCAs without vasculitis manifestations suggests that ANCAs alone are not enough to induce 
vasculitis. Furthermore, high ANCA titres may persist without activation of vasculitis. The pathogenic role of ANCA-MPO in vasculitis 
seems to be related to sub-classes of anti-MPO antibodies[20].The mechanism by which the ATD, and particularly, thiouracils, may induce 
AAV remains to be elucidated[8]. Jiang et al. showed that PTU, among other medications, was highly cytotoxic in the presence of activated 
neutrophils[21]. Treatment depends on vasculitis localization and clinical severity. Minor symptoms respond well to cessation of the ATD. In 
cases of seriousrenal damage, treatment with steroids with or without cyclophosphamide should be considered. In cases of life-threatening 
pulmonary haemorrhage, in addition to steroids and immunosuppressive drugs, plasmapheresis is warranted[18]. Derivatives of imidazole 
are preferred, in cases of relapse, before considering a radical treatment involving surgery or radioactive iodine therapy. Prognosis is less 
severe than primary ANCA vasculitis, and death due to anti-thyroid therapy-induced AAV is exceptional, related generally to severe alveolar 
haemorrhage[22].
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Case Sex/age Reference Disease BTU treatment duration Symptoms
1 M/70 Tieulie et al. [5] Graves’ 36 months Renal failure, psychiatric manifestations, anaemia
2 F/28 Kaaroud et al. [6] Graves’ 24 months Arthralgia, dyspnoea, renal failure
3 F/22 Jarraya et al. [7] Graves’ 12 months General symptoms, renal failure
4 F/36 Braham et al. [8] Graves’ 36 months General symptoms, anaemia, renal failure
5 F/8 Thabet et al. [9] Graves’ 16 months Dyspnoea, pulmonary haemorrhage
6 F/12 Hachicha et al. [10] Graves’ 18 months Purpura, renal failure
7 F/21 Frigui et al. [11] Graves’ 24 months Fever, arthralgia, purpura, pulmonary haemorrhage, proteinuria 
8 F/37 Frigui et al. [11] Graves’ 84 months Purpura, renal failure, axonal neuropathy
9 F/40 Frigui et al. [11] Graves’ 22 months Fever, arthralgia, leg ulcers
10 M/50 Trimeche Ajmi et al. [3] Graves’ 8 months General symptoms, renal failure
11 F/28 Chebbi et al. [12] Graves’ 15 months Necrotic purpura, fever
12 F/48 Houissa et al. [13] Graves’ 12 months Leg ulcers, arthralgia, renal failure, anaemia
13 F/36 Kaaroud et al. [14] Graves’ 36 months General symptoms, renal failure, alveolar haemorrhage
14 F/61 Kaaroud et al. [14] Graves’ 6 months Arthralgia, renal failure
15 F/36 Kaaroud et al. [14] Graves’ 49 months General symptoms, fever, anaemia, renal failure
16 F/33 Kaaroud et al. [14] Graves’ 120 months General symptoms, fever, alveolar haemorrhage, renal failure
17 F/19 Kaaroud et al. [14] Graves’ 36 months Fever, renal failure
18 F/68 Delattre et al. [15] Graves’ >12 months Purpura, arthralgia, renal failure
Case Pathology ANCA MPO Management Outcome ANCA control
1 Pauci-immune necrotizing GN P + Ster, ceased BTU, carbimazole/RI therapy Improved Decreased
2 Crescentic GN P + Haemodialysis, Ster, CYC, ceased BTU Chronic renal failure Persistence
3 Crescentic GN ? + No treatment, BTU continued Stable ?
4 Pauci-immune necrotizing GN P + Ster, CYC, ceased BTU Improved Persistence
5 None available P + (anti LF, Elast) Ster, ceased BTU Improved Negative
6 Cutaneous vasculitis, 
pauci-immune necrotizing GN
? + Ster, ceased BTU Improved Negative
7 Necrotizing GN P + Ster, ceased BTU, RI therapy Improved Negative
8 Leucocytoclastic cutaneous 
vasculitis
P + Ster, ceased BTU, RI therapy Improved Negative
9 Leucocytoclastic cutaneous 
vasculitis
P + Ster, ceased BTU, RI therapy Improved ?
10 Pauci-immune necrotizing GN P + Ster, CYC, ceased BTU Improved Persistence
11 Leucocytoclastic cutaneous
 vasculitis
P + Ceased BTU, carbimazole/RI therapy Improved Negative
12 Pauci-immune necrotizing GN, P + Ster, CYC, ceased BTU Improved Decreased
13 Leucocytoclastic cutaneous
 vasculitis
P + Ster, CYC, plasma exchange, ceased BTU Improved Persistence
14 Crescentic GN P + Ster, CYC, ceased BTU Stable ?
15 Crescentic GN P + Ster, ceased BTU, haemodialysis Chronic renal failure ?
16 Crescentic GN C - Ster, CYC, ceased BTU, 
haemodialysis/plasma exchange
Death (septicaemia) ?
17 Crescentic GN + ? Ster, ceased BTU Improved ?
18 Necrotizing GN P + Ster, CYC, ceased BTU, thyroidectomy Improved Negative
 
Table 2. Cases of BTU-induced ANCA-associated vasculitis: a review of the literature
BTU: benzylthiouracil; Ster: steroid; CYC: cyclophosphamide; RI: radioactive iodine therapy; GN: glomerulonephritis
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